0R19 Stock Overview
Develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 4/6 |
My Notes
Capture your thoughts, links and company narrative
Becton, Dickinson and Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$247.89 |
| 52 Week High | US$250.89 |
| 52 Week Low | US$218.38 |
| Beta | 0.42 |
| 1 Month Change | 9.10% |
| 3 Month Change | 5.26% |
| 1 Year Change | 4.59% |
| 3 Year Change | -7.95% |
| 5 Year Change | -0.93% |
| Change since IPO | 101.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0R19 | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | 2.3% | 2.7% | 2.0% |
| 1Y | 4.6% | -4.0% | 10.8% |
Return vs Industry: 0R19 exceeded the UK Medical Equipment industry which returned -4% over the past year.
Return vs Market: 0R19 underperformed the UK Market which returned 10.8% over the past year.
Price Volatility
| 0R19 volatility | |
|---|---|
| 0R19 Average Weekly Movement | 2.8% |
| Medical Equipment Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.8% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0R19 has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0R19's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1897 | 74,000 | Tom Polen | www.bd.com |
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation systems, and medication inventory optimization and tracking systems; hemodynamic monitoring systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers.
Becton, Dickinson and Company Fundamentals Summary
| 0R19 fundamental statistics | |
|---|---|
| Market cap | US$71.81b |
| Earnings (TTM) | US$1.71b |
| Revenue (TTM) | US$20.18b |
42.1x
P/E Ratio3.6x
P/S RatioIs 0R19 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0R19 income statement (TTM) | |
|---|---|
| Revenue | US$20.18b |
| Cost of Revenue | US$11.02b |
| Gross Profit | US$9.16b |
| Other Expenses | US$7.46b |
| Earnings | US$1.71b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 06, 2025
| Earnings per share (EPS) | 5.88 |
| Gross Margin | 45.41% |
| Net Profit Margin | 8.45% |
| Debt/Equity Ratio | 77.7% |
How did 0R19 perform over the long term?
See historical performance and comparisonDividends
1.7%
Current Dividend Yield65%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/01 05:00 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Becton, Dickinson and Company is covered by 40 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Ishan Majumdar | Baptista Research |
| Adam Feinstein | Barclays |